Profile data is unavailable for this security.
About the company
Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.
- Revenue in USD (TTM)1.15bn
- Net income in USD202.97m
- Incorporated1981
- Employees3.05k
- LocationBio-Techne Corp614 MCKINLEY PL N EMINNEAPOLIS 55413United StatesUSA
- Phone+1 (612) 379-8854
- Fax+1 (612) 656-4400
- Websitehttps://www.bio-techne.com/
Mergers & acquisitions
Acquired company | TECH:NSQ since announced | Transaction value |
---|---|---|
Lunaphore Technologies SA | -0.48% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Repligen Corp | 607.45m | 14.84m | 8.87bn | 1.78k | 629.03 | 4.50 | 105.04 | 14.61 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
Catalent Inc | 4.14bn | -1.18bn | 9.89bn | 17.80k | -- | 2.72 | -- | 2.39 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | -0.4346 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Exact Sciences Corp | 2.53bn | -240.23m | 9.98bn | 6.50k | -- | 3.17 | -- | 3.94 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 11.21bn | 20.00k | 25.53 | 3.08 | 14.49 | 2.73 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Sarepta Therapeutics Inc | 1.40bn | 16.90m | 12.02bn | 1.31k | 1,595.71 | 12.50 | 204.60 | 8.56 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Medpace Holdings Inc | 1.96bn | 312.32m | 12.10bn | 5.80k | 39.80 | 17.98 | 35.61 | 6.17 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
United Therapeutics Corporation | 2.50bn | 1.05bn | 12.26bn | 1.17k | 13.08 | 2.29 | 11.09 | 4.91 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Viatris Inc | 15.36bn | -56.10m | 12.54bn | 38.00k | -- | 0.6263 | 4.74 | 0.8162 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
BIO-TECHNE Corp | 1.15bn | 202.97m | 12.67bn | 3.05k | 63.94 | 6.29 | 40.41 | 10.98 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Incyte Corp | 3.77bn | 745.44m | 12.90bn | 2.52k | 17.44 | 2.39 | 15.53 | 3.42 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Natera Inc | 1.21bn | -365.46m | 13.20bn | 3.28k | -- | 16.55 | -- | 10.92 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.14bn | 1.45k | 38.61 | 5.92 | 36.05 | 7.13 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 14.41bn | 3.40k | 71.84 | 2.84 | 46.37 | 5.83 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 17.59m | 11.19% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 10.19m | 6.48% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.37m | 4.05% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 5.53m | 3.52% |
BAMCO, Inc.as of 31 Mar 2024 | 5.00m | 3.18% |
BlackRock Advisors LLCas of 31 Mar 2024 | 4.03m | 2.56% |
Geode Capital Management LLCas of 31 Mar 2024 | 3.84m | 2.44% |
Neuberger Berman Investment Advisers LLCas of 31 Mar 2024 | 3.57m | 2.27% |
D. F. Dent & Co., Inc.as of 31 Mar 2024 | 3.40m | 2.16% |
Mairs & Power, Inc.as of 31 Mar 2024 | 3.12m | 1.98% |